Vericel (NASDAQ:VCEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a buy rating in a report released on Sunday.

A number of other equities analysts have also recently weighed in on VCEL. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Truist Financial decreased their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, Zacks Research lowered shares of Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Vericel Price Performance

VCEL stock opened at $36.58 on Friday. The firm has a 50 day simple moving average of $37.77 and a two-hundred day simple moving average of $36.29. The stock has a market cap of $1.85 billion, a PE ratio of 152.42 and a beta of 1.17. Vericel has a one year low of $29.24 and a one year high of $63.00.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. Vericel had a net margin of 5.06% and a return on equity of 4.30%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. On average, research analysts expect that Vericel will post 0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Ameritas Advisory Services LLC bought a new position in shares of Vericel during the second quarter valued at $30,000. Huntington National Bank raised its stake in shares of Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after buying an additional 273 shares during the period. Farther Finance Advisors LLC lifted its holdings in Vericel by 116.5% during the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 522 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new position in shares of Vericel during the 3rd quarter valued at $31,000. Finally, CWM LLC lifted its position in shares of Vericel by 101.3% in the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 694 shares in the last quarter.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.